SEARCH

SEARCH BY CITATION

References

  • Anchi T, Tamura K, Furihata M, Satake H, Sakoda H, Kawada C, Kamei M, Shimamoto T, Fukuhara H, Fukata S, Ashida S, Karashima T, Yamasaki I, Yasuda M, Kamada M, Inoue K, Shuin T (2012) SNRPE is involved in cell proliferation and progression of high-grade prostate cancer through the regulation of androgen receptor expression. Oncol Lett 3:264268.
  • Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS (2004) Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology, 64:537541; discussion 542–533.
  • Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:2529.
  • Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66:794802.
  • Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA (2005) CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 4:291298.
  • Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N (2009) Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 124:29892996.
  • Bethel CR, Chaudhary J, Anway MD, Brown TR (2009) Gene expression changes are age-dependent and lobe-specific in the brown Norway rat model of prostatic hyperplasia. Prostate 69:838850.
  • Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolo G, Barboro P, Parodi S, Patrone E, Balbi C (2003) Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate 55:259264.
  • Bowen C, Gelmann EP (2010) NKX3.1 activates cellular response to DNA damage. Cancer Res 70:30893097.
  • Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M (1986) Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med 146:21592164.
  • Carmine AA, Brogden RN, Heel RC, Romankiewicz JA, Speight TM, Avery GS (1983) Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 26:279333.
  • Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI (2006) The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 1765:85100.
  • Chan JM, Jou RM, Carroll PR (2004) The relative impact and future burden of prostate cancer in the United States. J Urol, 172:S13S16; discussion S17.
  • Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725730.
  • Colsky J, Meiselas LE, Rosen SJ, Schulman I (1955) Response of patients with leukemia to 8-azaguanine. Blood 10:482492.
  • Gallagher RP, Fleshner N (1998) Prostate cancer: 3. Individual risk factors. CMAJ 159:807813.
  • Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21:11561167.
  • Haverkamp J, Charbonneau B, Ratliff TL (2008) Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem 103:13441353.
  • Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S (2008) Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 14:47194725.
  • da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:4457.
  • Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249264.
  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:6990.
  • Kanehisa M (2002) The KEGG database. Novartis Found Symp, 247:91101; discussion 101-103, 119-128, 244-152.
  • Klein EA, Silverman R (2008) Inflammation, infection, and prostate cancer. Curr Opin Urol 18:315319.
  • Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:19291935.
  • Linton DK, Hamdy FC (2004) Early diagnosis and surgical management of prostate cancer. Ann Urol (Paris) 38:137147.
  • Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM (2007) Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 12:42544266.
  • Nelson WG, De Marzo AM, Yegnasubramanian S (2009) Epigenetic alterations in human prostate cancers. Endocrinology 150:39914002.
  • Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T (2008) TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14:33953400.
  • Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 3 Article 3.
  • Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:14011408.
  • Team RDC. (2008). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215224.
  • Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644648.
  • Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448:595599.
  • Watson PM, Watson DK (2010) Alternative splicing in prostate and breast cancer. Open Cancer J 3:6276.
  • Weitekamp MR, Aber RC (1983) Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA 249:6971.
  • Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001) Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 68:901911.
  • Yang Z, Chang YJ, Miyamoto H, Yeh S, Yao JL, di Sant'Agnese PA, Tsai MY, Chang C (2007) Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54. Endocrinology 148:13401349.
  • Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG (2008) DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68:89548967.
  • Yi Y, Nandana S, Case T, Nelson C, Radmilovic T, Matusik RJ, Tsuchiya KD (2009) Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer. Mol Cytogenet 2:18.
  • Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284287.
  • Zheng XY, Zhang P, Xie LP, You QH, Cai BS, Qin J (2012) Prostate-specific Antigen Velocity (PSAV) and PSAV per Initial Volume (PSAVD) for Early Detection of Prostate Cancer in Chinese Men. Asian Pac J Cancer Prev 13:55295533.